Company Encyclopedia
View More
name
Xtrk MSCI Eafe Hdy Hdg
HDEF.US
News
View More

Sanofi Closes on UK Biotechnology Company Vicebio

Sanofi Closes on UK Biotechnology Company Vicebio

marketscreener·
US
SNYNF
0.00%
marketscreener·
US
SNYNF
0.00%

Sanofi Completes Acquisition of Vicebio

Sanofi has completed the acquisition of Vicebio Ltd, enhancing its vaccine portfolio with an early-stage candidate for RSV and HMPV. This acquisition leverages Vicebio's Molecular Clamp technology, adding a non-mRNA option to Sanofi's respiratory vaccine pipeline, thus expanding choices for physicians and patients. The original content was published by Sanofi via GlobeNewswire on December 4, 2025.

Reuters·
US
SNYNF
0.00%
Reuters·
US
SNYNF
0.00%

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-Driven Antibody Optimisation Programs

LabGenius Therapeutics announced a second collaboration with Sanofi. This collaboration combines LabGenius' AI/ML-driven antibody design capabilities with Sanofi's expertise in the development of therapeutic NANOBODY molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA platform to optimise NANOBODY molecules for multiple new targets in the area of inflammation.

marketscreener·
US
SNYNF
0.00%
marketscreener·
US
SNYNF
0.00%

Sanofi and Regeneron win EU approval for Dupixent in chronic spontaneous urticaria

Sanofi SA and Regeneron have received EU approval for Dupixent (dupilumab) to treat moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older. This marks the first targeted treatment approval for CSU in over a decade, based on positive phase 3 clinical trials. Dupixent is now approved in the EU, US, and Japan for this indication.

Reuters·
US
SNYNF
0.00%
US
REGN
-0.12%
Reuters·
US
SNYNF
0.00%
US
REGN
-0.12%

US vaccine committee to vote this week on delay of hepatitis B shots

The US vaccine advisory committee, led by Health Secretary Robert F. Kennedy Jr., will vote this week on delaying hepatitis B shots for most American children. The committee has not decided on the duration of the delay. The idea, promoted by Kennedy, aims to thoroughly test vaccines before administering them to vulnerable groups. A review found that the current policy reduces infections by over 95%. The committee has not discussed potential supply issues with vaccine makers. The meeting is scheduled for Thursday and Friday.

Reuters·
US
SNYNF
0.00%
Reuters·
US
SNYNF
0.00%
© 2025 Longbridge｜Disclaimer